🇺🇸 calcineurin inhibitors in United States

36 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cytomegalovirus Infection — 6 reports (16.67%)
  2. Chronic Graft Versus Host Disease — 4 reports (11.11%)
  3. Drug Ineffective — 4 reports (11.11%)
  4. Off Label Use — 4 reports (11.11%)
  5. Acute Graft Versus Host Disease — 3 reports (8.33%)
  6. Death — 3 reports (8.33%)
  7. Drug Interaction — 3 reports (8.33%)
  8. Mucosal Inflammation — 3 reports (8.33%)
  9. Renal Impairment — 3 reports (8.33%)
  10. Sepsis — 3 reports (8.33%)

Source database →

calcineurin inhibitors in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is calcineurin inhibitors approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for calcineurin inhibitors in United States?

Nanfang Hospital, Southern Medical University is the originator. The local marketing authorisation holder may differ — check the official source linked above.